AUTHORS
Omar Alkharabsheh, MD, Meletios-Athanasios (Thanos) C. Dimopoulos, MD2, Fredrik Schjesvold, MD,PhD3, Chengcheng Fu, MD, PhD4, Darrell White, MD5, Cecily Forsyth, MBBS, FRACP, FRCPA6, Vania Hungria, MD, PhD7, Preetam Kalaskar8, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA9, Maika Klaiber-Hakimi10, Gergely Varga, PhD11, Zhongjun Xia, MD, PhD12, Chieh-Lin Teng13, Armando Santoro, MD14, Wee Joo Chng15, Maria Esther Clavero Sanchez, MD16, Hannah Hunter, FRCPath, MB, MRCP17, Junichiro Yuda, MD, PhD18, Junya Kuroda, MD, PhD19, Yizhe Chen, PhD20, Tracy T. Chow, PhD21, George Zhang22, Antoine Tinel23, Alberto Rocci24, Jessica Katz, MD, PhD25, Paul G. Richardson, MD26
AFFILIATIONS
1 USA Health Mitchell Cancer Institute, University of South Alabama, Mobile, AL, United States
2 Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece, Department of Medicine, Korea University College of Medicine, Seoul, Korea, Rep. of South
3 Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
4 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China
5 Division of Hematology, Dalhousie University and Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada
6 Department of Haematology, Gosford Hospital, Gosford, NSW, Australia
7 Clinica São Germano, São Paulo, Brazil
8 Mumbai Oncocare Centre, Thane, India
9 Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia
10 Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany
11 Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary
12 Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
13 Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
14 IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Italy
15 Department of Medicine, Yong Loo Lin School of Medicine and Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore, National University Cancer Institute, National University Health System, Singapore, Singapore
16 Hospital Universitario Virgen de las Nieves, Granada, Spain
17 University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
18 Department of Hematology, National Cancer Center Hospital East, Chiba, Japan
19 Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan
20 Bristol Myers Squibb, Princeton, NJ, United States
21 Bristol Myers Squibb, Princeton, NJ, United States
22 Bristol Myers Squibb, Princeton, NJ, United States
23 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
24 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
25 Bristol Myers Squibb, Princeton, NJ, United States
26 Dana-Farber Cancer Institute, Boston, MA, United States
ABSTRACT
Introduction: Initial results from the phase 3 SUCCESSOR-2 trial (NCT05552976) showed significantly improved progression-free survival (PFS) with MeziKd vs Kd (hazard ratio, 0.48) in anti-CD38 monoclonal antibody (mAb)- and lenalidomide (LEN)-exposed patients (pts) with RRMM from first relapse (Dimopoulos MA, et al. Lancet 2026;408:219–233). Aligned with the goals of the US Food and Drug Administration’s Project Optimus, SUCCESSOR-2 used a novel 2-stage, inferentially seamless design to evaluate the totality of efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) at 3 dose levels of Mezi in combination with Kd vs Kd alone before advancing to a single optimized dose in a larger cohort. Here, we report the results of the dose-optimization stage of the trial.
Methods: In stage 1, pts were randomized 3:3:3:2 to 1 of 3 Mezi doses (1.0 mg, 0.6 mg, or 0.3 mg) or to Kd. The independent data monitoring committee reviewed the totality of the data for stage 2 dose selection, while the study team remained blinded. For this abstract, we evaluated PFS, overall response rate (ORR), complete response or better (≥CR), duration of response (DOR), time to response (TTR), safety, PK, and PD at each dose level (1.0 mg: n=63; 0.6 mg: n=63; 0.3 mg: n=64; Kd: n=45; data cutoff Jan 15, 2026). Immunomodulation in peripheral blood was assessed by flow cytometry.
Results: Baseline characteristics of stage 1 pts were generally consistent across Mezi dose groups and Kd. Median age was 66–68 y and most pts were refractory to both anti-CD38 mAbs and LEN (1.0 mg: 73.0%; 0.6 mg: 71.4%; 0.3 mg: 67.2%; Kd: 80.0%). All groups had a median of 3 prior lines of treatment (tx), with nearly half of pts in each group having 1–2 prior lines (1.0 mg: 42.9%; 0.6 mg: 44.4%; 0.3 mg: 45.3%; Kd: 42.2%). Median tx duration in stage 1 was longer for all MeziKd doses (10.1–11.0 mo) than Kd (7.4 mo). With median follow-up of 20.3–22.1 mo, tx discontinuation was lowest with 1.0 mg Mezi vs 0.6 mg, 0.3 mg, or Kd (69.8% vs 73.0%, 76.6%, or 84.4%, respectively); the most common reason for tx discontinuation in all groups was progressive disease (41.3%, 47.6%, 46.9%, 66.7%, respectively).
Among pts receiving Mezi, median PFS was longest with 1.0 mg vs 0.6 mg and 0.3 mg (18.0 mo [95% CI, 10.6–22.4] vs 14.1 mo [9.2–18.2] and 11.2 mo [8.4–18.4]); median PFS for all Mezi doses exceeded that with Kd (7.4 mo [4.2–10.9]). Similarly, 1.0 mg Mezi had the highest ORR (77.8% vs 76.2%, 67.2%, and 62.2% for 1.0 mg vs 0.6 mg, 0.3 mg, and Kd, respectively). Deeper responses were observed with 1.0 mg Mezi than with the lower doses or Kd (≥CR rate: 36.5% vs 28.6%, 21.9%, and 4.4%, respectively). Median DOR was longest with 1.0 mg vs 0.6 mg, 0.3 mg, and Kd (18.9 mo [95% CI, 13.6–not reached (NR)] vs 16.0 mo [9.4–NR], 17.9 mo [9.2–23.7], and 9.7 mo [6.0–21.4]). Median TTR was 1.1 mo at all Mezi doses and 1.0 mo with Kd.
The overall safety profile was similar across Mezi doses; any-grade tx-emergent adverse events (TEAEs) occurred in all pts and grade 3/4 TEAEs in most pts (1.0 mg: 98.4%; 0.6 mg: 96.8%; 0.3 mg: 89.1%). The most common grade 3/4 TEAEs with MeziKd were neutropenia (71.4%, 57.1%, and 53.1%, respectively) and thrombocytopenia (47.6%, 30.2%, and 20.3%, respectively). Grade 3/4 infections were reported for 46.0%, 55.6%, and 42.2% of pts, respectively, with 25.4%, 27.0%, and 15.6% of pts reporting grade 3/4 pneumonia. TEAEs leading to Mezi dose reduction occurred in 47.6%, 33.3%, and 21.9% of pts; no trend was observed in the rates of TEAEs leading to Mezi dose interruption (87.3%, 93.7%, and 81.3%, respectively).
MeziKd exhibited dose-proportional PK. Immunomodulatory activity was observed across all doses, with a trend of greater increase in proliferative (Ki67+) and activated (HLA-DR+) CD4+ T cells at the higher doses.
Conclusions: The innovative 2-stage, inferentially seamless design utilized for SUCCESSOR-2 enabled rigorous, data-driven benefit–risk evaluation for dose selection, without compromising the integrity of subsequent analyses. The 1.0-mg dose of Mezi plus Kd demonstrated the most favorable efficacy outcomes, including longer PFS, deeper responses, and greater immunomodulatory activity. Higher rates of hematologic TEAEs were observed at higher Mezi doses, but without an increase in high-grade infections, resulting in an overall manageable safety profile. Together, these findings support 1.0 mg as the recommended Mezi dose in combination with Kd.
DISCLOSURES
Omar Alkharabsheh, MD: No relevant conflicts of interest to declare.